 |
(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide |
|---|---|
| Trade Name | |
| Orphan Indication | Paroxysmal nocturnal hemoglobinuria |
| EU Market Approval | EU |
| EU Designation Date | 2017-12-12 00:00:00 |
| Sponsor | FGK Representative Service GmbH |
